Walgreens expands safe drug disposal to all pharmacies

Walgreens said it is expanding its safe drug disposal program to provide year-round drug disposal options in all of its pharmacies nationwide, at no cost to customers. All Walgreens pharmacies that do not currently offer a safe medication disposal kiosk now offer DisposeRx packets or other drug disposal options, available upon request for customers, to safely discard unwanted medications at home. Read More →

Read More
Brea Neri
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII)

The Lancet - In patients with uncontrolled type 2 diabetes on oral antidiabetic drugs, initial injectable therapy with insulin degludec plus liraglutide resulted in fewer patients reaching the treatment intensification criterion during 104 weeks versus insulin glargine 100 units/mL, with longer durability of the treatment effect with insulin degludec plus liraglutide. Read More →

Read More
Brea Neri
Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden

BMJ - This study suggests that gabapentinoids are associated with an increased risk of suicidal behavior, unintentional overdoses, head/body injuries, and road traffic incidents and offences. Pregabalin was associated with higher hazards of these outcomes than gabapentin. Read More →

Read More
Brea Neri
Anticholinergic Drug Exposure and the Risk of Dementia

Exposure to several types of strong anticholinergic drugs including anticholinergic antidepressants, antiparkinson drugs, antipsychotic drugs, bladder antimuscarinics, and antiepileptic drugs is associated with an increased risk of dementia. These findings highlight the importance of reducing exposure to anticholinergic drugs in middle-aged and older people. Read More →

Read More
Brea Neri
AMA passes opioid policies to end barriers to non-opioid treatment

AMA - approved several opioid-related policies at its Annual Meeting that are intended to put the focus of pain treatment back on patients and away from arbitrary third-party controls. The resolutions take aim at obstacles to effective treatment that were enacted by state and federal authorities, as well as insurers, pharmacy benefit management companies (PBMs) and national pharmacy chains such as prior authorization, step therapy, and policies setting hard thresholds for prescriptions. Read More →

Read More
Brea Neri
New antimicrobial stewardship requirements for ambulatory health care organizations introduced

Joint Commission - Effective January 1, 2020, new antimicrobial stewardship requirements will be applicable to Joint Commission-accredited ambulatory health care organizations that routinely prescribe antimicrobial medications. The Joint Commission developed new requirements to help decrease misuse of antimicrobial medications, which contributes to antibiotic resistance and adverse drug events. Read More →

Read More
Brea Neri
Pain Management Task Force Issues Final Report on Best Practices for Treatment of Pain

HHS - The Pain Management Best Practices Inter-Agency Task Force released its final report on acute and chronic pain management best practices, calling for a balanced, individualized, patient-centered approach. It highlights five broad categories for pain treatment: medications, interventional procedures, restorative therapies, behavioral health, and complementary and integrative health approaches. Read More →

Read More
Brea Neri
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

FDA - approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. Read More →

Read More
Brea Neri
New Pharmacist Vaccine Administration Law Will Go Into Effect on October 1, 2019

New pharmacist vaccine administration law will go into effect on October 1, 2019. It adds Serogroup B meningococcal vaccines, human papillomavirus vaccine, and Hepatitis A vaccine to the list of vaccines that a pharmacist may administer to persons 18 or older pursuant to protocol. It also authorizes pharmacists to administer flu vaccine to patients at least ten (10) years old pursuant to protocol or to patients at least six (6) years old pursuant to a prescription order. Read More →

Read More
Brea Neri
FDA Approves Victoza (liraglutide) for the Treatment of Pediatric Patients 10 Years or Older with Type 2 Diabetes

FDA approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010. Read More →

Read More
Brea Neri
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis

FDA approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery which often cannot control this disease. Moreover, CRSwNP often occurs in combination with severe asthma. Read More →

Read More
Brea Neri
Potentially Inappropriate Prescribing Among Older Persons: A Meta-Analysis of Observational Studies

Potentially inappropriate prescribing (PIP) in older adults was significantly negatively associated with emergency room visits, adverse drug events, functional decline, health-related quality of life, and hospitalizations. This meta-analysis highlights the need to identify PIP in primary care and calls for further research on PIP interventions in primary care. Read More →

Read More
Brea Neri
Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes

Routine urine samples, received at the time of the annual diabetes review from people with type 2 diabetes in primary care, were assessed for adherence by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and found 28.1% of patients to be nonadherent to antidiabetic, antihypertensive, and/or lipid-lowering medications. This unique study shows that routine urine samples can be used for adherence testing screening by LC-MS/MS. Read More →

Read More
Brea Neri